BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:03 PM
 | 
May 28, 2010
 |  BC Extra  |  Clinical News

Mixed results for Recentin in mCRC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Recentin cediranib met one co-primary endpoint but missed the other in the Phase III HORIZON II trial to treat metastatic colorectal cancer (mCRC). Recentin plus FOLFOX or...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >